View Cart  

FDA to Pay Closer Attention to Extended-Release Generics After Teva’s Generic Wellbutrin Withdrawal

The FDA is improving its methods and standards for evaluating some extended-release generics after the withdrawal of Impax and Teva’s 300-mg Wellbutrin XL generic because the product was not therapeutically equivalent to its branded counterpart.

To View This Article:


Subscribe To Drug Industry Daily